The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

GLUE FINANCIAL STATEMENTS

Monte Rosa Therapeutics Inc — balance sheet, income statement and cash flow trends

GLUEMonte Rosa Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-100 M0100 M202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue28.7 M $Gross Profit26.7 M $ · 93%Operating Income-181.9 M $ · -633%Pre-tax Income-164 M $ · -571%Net Income to Owners-161.1 M $ · -561%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue28.7 M $-83.9%
Gross Profit26.7 M $-85.0%
Operating Income-181.9 M $-1,315.7%
EBITDA-155.8 M $-523.9%
Net Income to Owners-161.1 M $-766.7%

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0250 M500 M750 M202120222023202420252026

Capital Structure

Q2 2026
Total Assets696.1 M
  • Equity487.3 M $70%
  • Current Liabilities66.8 M $10%
  • Long-term Liabilities144.2 M $21%

Key Figures

YoY change
Total Assets696.1 M $+93.6%
Total Liabilities211 M $+130.6%
Total Equity487.3 M $+81.8%
Cash & ST Investments621.1 M $+113.7%
Total Debt38 M $-7.6%
Net Debt-52.1 M $—

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-100 M0100 M202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-600 M-400 M-200 M0-61.4 M $Operating-577.8 M $Investing689.9 M $Financing50.6 M $Net Change

Key Figures

YoY change
Operating Cash Flow-61.4 M $-321.7%
Capital Expenditures9.9 M $+155.6%
Free Cash Flow-71.3 M $-399.0%
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on GLUE

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 11, 26. This content is for informational purposes only and is not investment advice.